Armata Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Armata Pharmaceuticals, Inc. (NYSE American: ARMP) on October 3, 2024, covering events occurring on September 30, 2024. The filing addresses the departure of a senior financial officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: Richard Rychlik, Vice President and Corporate Controller, concluded his employment effective September 30, 2024.
- Separation Agreement: A Confidential Separation and Release Agreement was executed on September 30, 2024.
- Compensation Terms: Mr. Rychlik is entitled to continued base salary payments through December 31, 2024, and subsidized COBRA premiums for the same period, contingent upon compliance with the agreement.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or general business risks. The primary contingency noted is that the separation benefits are subject to Mr. Rychlik's compliance with the terms of the Separation Agreement.
Investor Verification Checklist
- Verify the appointment of a new Corporate Controller or interim financial leadership.
- Review the full text of the Confidential Separation and Release Agreement (Exhibit 10.1) for specific release terms.
- Monitor upcoming filings for any impact on internal controls or financial reporting timelines due to the controller's departure.